Theme: Advances and Innovations in Development of Biotherapeutics

Biotherapeutics 2017
Past Report of Biopharma 2016

Biotherapeutics 2017

Conference Series LLC is a renowned organization that organizes highly notable  conferences throughout the globe. Currently we are bringing forth World Congress on Biotherapeutics” (Biotherapeutics 2017) scheduled to be held during May 22-23, 2017 at Mexico city, Mexico. The conference invites all the participants across the globe to attend and share their insights and convey recent developments in the field of Biotherapeutics.

Conference Series LLC organizes a conference series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Track 1: Biotherapeutics

Biotherapeutics usually refers to therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics are basically agents, used to treat and avoid human disease by interrelating with the microbial ecology of the host. Biotherapeutics have the ability to target specific molecules within the human body, and have a good track record with patient safety. Manufacturing biotherapeutics is complex, as they are larger compounds in both size and structure, and can be sensitive to environmental conditions. Additionally, Bio therapeutic manufacturing includes many regulations such as signal processing, biology and engineering process control. Moreover, they require sophisticated production and control processes and are dependent upon the host cells of living organisms to produce the necessary active pharmaceutical substances.

Track 2: Synthetic Immunology

Synthetic immunology including the development and regeneration of immune cells, immune organ development and artificial regeneration, and the synthetic approach towards understanding human immune system. Immune cell therapy involves engineering or isolating cancer-fighting immune cells (T cells), growing large numbers of these cells in the laboratory and then infusing them back into patients.

Track 3: MicroRNA Biotherapeutics

MicroRNAs (miRNAs) are a class of small (18–24 nucleotide long) RNAs that are involved in regulation of gene expression by targeting messenger RNAs (mRNA). Deregulation of miRNAs has been reported in many human diseases such as cancer, cardiovascular disease and autoimmune disorders. Since miRNAs can be efficiently inhibited by modified/synthetic antisense oligonucleotides, there is great interest in developing anti-miRNA therapies for several diseases. In addition to tissues/cells, miRNAs were also detected in various biofluids such as serum/plasma, urine, saliva, cerebrospinal fluid and amniotic fluid. Usually miRNAs present in biofluids are packed in exosomes or associated to proteins or lipoproteins and hence protected from enzymatic degradation. Because of their stability and specificity, several studies demonstrated the utility of circulating miRNAs as diagnostic and prognostic biomarkers in disease such as cancer, cardiac disease and autoimmune disease. More recently, microRNAs have been investigated as potential safety biomarkers. Thus miRNAs received much attention not only as global intracellular and intercellular regulators but also as therapeutic targets and disease or safety biomarkers. Hence there is great interest in miRNA identification and profiling.

Track 4: Oncolytic Virotherapy

Oncolytic Virotherapy is the experimental treatment of cancer patients based on the administration of replication-competent viruses that selectively destroy tumor cells but leave healthy tissue unaffected. Virotherapy is a safe and effective cancer treatment. It improves time to progression, survival and quality of life for cancer patients. Virotherapy is particularly important in the treatment of those cancers types, which are insensitive to radiotherapy or chemotherapy, for example, melanoma.

Oncolytic viruses refer to those viruses that are able to eliminate malignancies by direct targeting and lysis (killing) of cancer cells within the tumor, leaving non-cancerous cells unharmed. Oncolytic viruses by definition have a natural attraction to cancer cells (tropism), though their safety profile in patients, selectivity and replication competence vary significantly by type and strain of virus.

Track 5: Immunopharmacotherapy

Immunopharmacotherapy is the treatment or prevention of disease by taking measures to increase immune system functioning (as by the administration of antibodies or hypo sensitization). Immune cell therapy involves engineering or isolating cancer-fighting immune cells (T cells), growing large numbers of these cells in the laboratory and then infusing them back into patients. Immune cells are naturally present in most tumors, but usually have been deactivated by the cancer or simply lack the numbers to eradicate the cancer on their own.

Track 6: Cystine-Knot Micro-Proteins

Cystine-knot microproteins are a class of very small, highly stable proteins that can be administered orally and have considerable therapeutic potential as potent, selective modulators of bimolecular interactions. Their eponymous motif comprises a rigid structured core formed by six disulfide-connected cysteine residues, which accounts for its exceptional stability towards thermic or proteolytic degradation. Since they display a remarkable sequence tolerance within their disulfide-connected loops, these molecules are considered promising frameworks for peptide-based pharmaceuticals.

Track 7: Innovative Therapies for Serious Diseases

Innovative Therapies includes correcting a defective gene, inserting a gene-drug, grafting cells capable of regenerating healthy tissue. In patients with rare, severe immune-mediated inflammatory diseases (IMIDs), biologics are often the last treatment option when standard therapy with classical immunosuppressive drugs fails. However, clear guidelines on biologic prescription in these diseases are often lacking. A major reason is that proper randomized controlled trials (RCTs) are difficult to design due to the low prevalence, heterogeneity of patients, and the severe medical condition of patients. Since RCTs are usually required for registration of therapy for a specific disease, physicians often prescribe biologics off-label in these diseases. Off-label prescription can be defined as the prescription of a drug for conditions other than current registered indications. This means that the drug is approved by either FDA or EMA for a certain disease, yet there is no definitive proof for the efficacy of the specific drug for other conditions. The physician’s decision to prescribe off-label in such cases is often based on the pathophysiology of the disease or shared symptoms with other diseases in which the biologic has proven to be effective. This is called rational prescription and may lead to innovative treatment options, especially in rare diseases.

Track 8: In-vitro Somatic Hyper mutations

Somatic hypermutation (SHM) is a diversity generating, regulated cellular mechanism displayed by the adaptive immune response. It is a natural process embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. SHM is a critical, endogenous process that generates the essential antibody diversity required to develop a natural immune response to pathogens.

Track 9: Glycobiology of Antibodies

Glycobiology has emerged which combines expertise in both carbohydrate biochemistry and molecular biology. Carbohydrate sequences contain much structural information which is exploited in many forms of biological recognition. Examples of the interaction of cells with cytokines, hormones, toxins, antibodies, lectins, bacteria, viruses, and other cells have all been demonstrated to involve carbohydrate recognition.

Track 10: Synthetic Protein Biologics

Biologics are protein based therapeutics obtained from humans, animals and plants. These can be large complex proteins such as hormones or antibodies or smaller antibody fragments. Biologics have been highly successful both as therapeutics and as diagnostics. However, large complex molecules like monoclonal antibodies are costly to manufacture; the biopharmaceutical industry is therefore interested in new strategies and production platforms to reduce cost.

Track 11: Advances in Antibody-Drug Conjugates

Antibody Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds.  ADCs are an attractive therapy for cancer because the ADC provides a means to target highly potent cytotoxic small molecules to specific tumor cells that bear an antigen recognized by the mAb portion of the ADC. By selecting an antigen that is highly expressed on the surface of tumor cells, but has a much lower abundance in normal tissue, the ADC delivers its small molecule payload selectively to the tumor mass. ADCs must therefore be designed to consist of mAbs that are internalized into the target tumor cell of interest, employ linkers that are stable in systemic circulation but that break down only inside the target cell and deliver payloads that are highly potent. As therapeutics, they combine the exquisite specificity of antibodies, enabling discrimination between healthy and diseased tissue, with the cell-killing ability of cytotoxic drugs.

Track 12: Stem Cell Therapy

Stem cell therapy, also known as regenerative medicine, promotes the reparative response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. It is the next chapter of organ transplantation and uses cells instead of donor organs, which are limited in supply. Stem cells have the power to go to these damaged areas and regenerate new cells and tissues by performing a repair and a renewal process, restoring functionality. Regenerative medicine has the potential to provide a cure to failing or impaired tissues.

Track 13: Cancer Biotherapeutics

Cancer biotherapeutics encompasses all biologically derived materials that have been processed or engineered to treat cancer, including cancer-killing viruses, immune cell therapies and antibody therapies.  All of these therapies have mechanisms that enlist the immune system (are immunotherapeutic), are highly promising and targeted, and are the subject of much excitement in research. In contrast to conventional therapies, biotherapeutics for cancer treatment are not based on man-made chemicals that flood the system with toxins. Biotherapeutics are designed to specifically target cancer cells without harming healthy cells, which results in greater effectiveness and fewer, less severe, side effects. Even in early phase clinical trials, biotherapeutics have provided complete remission for a number of patients who had run out of treatment options.

Track 14: Clinical Biotherapeutics

Clinical Biotherapeutic aspects including study design, drug-drug interactions, QT assessment, immunogenicity, comparability, special populations (hepatic and liver failure), PK and PD, regulatory expectations of PK and PD characterization, as well as reviewing factors which influence the ADME of Biotherapeutics. The objectives of early clinical development of therapeutic proteins are the same as for small molecules i.e. to investigate the molecule in a manner that will gain necessary knowledge about its tolerability safety pharmacokinetics (PK) and if possible pharmacodynamics (PD) effects in the most appropriate human populations while simultaneously protecting their safety. However, there are specific features of proteins that must be considered when designing clinical pharmacology studies.

Track 15: Biotherapy

Biotherapy is the treatment to stimulate or restore the ability of the immune (defense) system to fight infection and disease. Biological therapies, sometimes called biotherapy, immunotherapy or biological response modifier therapy, is designed to repair, stimulate, or enhance your body’s own immune responses. Biological therapy is thus any form of treatment that uses the body's natural abilities that constitute the immune system to fight infection and disease or to protect the body from some of the side effects of treatment. Biotherapy often employs substances called Biological response modifiers (BRMs). The body normally produces low levels of BRMs in response to infection and disease. Large amounts of BRMs can be made in the laboratory to treat cancer, rheumatoid arthritis, and other diseases.

Track 16: Analytical Biotherapeutics

Analytical biotherapeutics include identity by microbiological characterization of the strain, purity (monosepsis), strength by determination of viability, development of cell based potency assays. This also includes advanced characterization technologies for a range of complex therapeutic proteins to provide complete understanding of the product, to ensure safety and efficacy, and to facilitate smooth and efficient interaction with the regulatory authorities. Analytical Biotherapeutics mainly focuses on assay and validation methods, hot spots identification, post-translational modifications, impurities, critical quality attributes formulation and stability.

Conference Series LLC is a renowned organization that organizes highly notable  conferences throughout the globe. Currently we are bringing forth World Congress on Biotherapeutics” (Biotherapeutics 2017) scheduled to be held during May 22-23, 2017 at Mexico city, Mexico. The conference invites all the participants across the globe to attend and share their insights and convey recent developments in the field of Biotherapeutics.

Conference Series LLC organizes a conference series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

2017 Highlights:

  • 300+ Participation (70 Industry: 30 Academia)
  • 5+ Keynote Speakers
  • 50+ Plenary Speakers
  • 20+ Exhibitors
  • 14 Innovative Educational Sessions
  • 5+ Workshops
  • B2B Meetings
Analytica-2015

Conference Series LLC organized 6th International Conference and Exhibition on Analytical & Bioanalytical Techniques during September 01-03, 2015 Valencia, Spain that got brilliant response. Eminent Scientists, researchers, business professionals and scholar students were participated during this prestigious conference. With the support and steerage of Organizing Committee Members, Editorial Board Members and amaze displays of all participants this outstanding summit became additional spectacular. The theme of the conference “Review of Advancements and therefore the Impacts of the Analytical & Bioanalytical Techniques” was dilated across the world by speeches from the participants and with boost of media partners and collaborators.

The conference was marked with the presence of far-famed scientists, proficient researchers, students and delegates representing from different countries ultimately driving the event into the trail of success.

Analytica 2015 Organizing Committee would like to thank the Moderator of the conference, Dr. Khondaker Miraz Rahman, king’s college of London and Transcriptogen Limited, UK, chair and co-chair of the conference and all other attendees who contributed a lot for the smooth functioning of the event.

Conference Series LLC would like to convey a great appreciation to following honourable guests and Keynote speakers

Alla Kloss, Sanofi,    USA
Istvan Halasz, PQ Corporation, USA
Makhapa Makhafola, Mintek,     South Africa
Alberto Chisvert, University of Valencia, Spain
Aly MOUSSA, Anses Lyon Laboratory, France
Florence Geneste, University of Rennes, France
Eduard Rogatsky, Yeshiva University, USA

Conference Series LLC on behalf of the conference, congratulates the Best Poster awardees for their outstanding performance in the field of Analytical & Bioanalytical Techniques and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavours. We would like to thank the Poster Competition Judge Dr. Aly MOUSSA, Anses Lyon Laboratory, France for his valuable time.

The Best Poster awardees were:

Alberto Chisvert, University of Valencia, Spain for Determination of N-nitroso-diethanolamine in cosmetic products by reversed-phase dispersive liquid-liquid micro-extraction followed by liquid chromatography

Guillermo Quiñones Reyes, Universitat de València, Spain for Hapten synthesis and monoclonal antibody-based immunoassays for cyprodinil residue analysis in food

Maha Said Ahmed Abd El-Tawwab, Cairo University, Egypt for Degradation kinetics of Aliskiren hemifumarate under stress conditions and its determination in tablets by stability indicating HPLC method and evaluated by  Dr. Aly MOUSSA, Anses Lyon Laboratory, France

Conference Series LLC has taken the privilege of felicitating Analytica 2015 Organizing Committee, Editorial Board Members, Honourable guests and Keynote Speakers who supported for the success of this event. With property excitement for grand success of this outstanding conference it's glad to announce next annual meeting 7th International Conference and Exhibition on Analytical & Bioanalytical Techniques to be control throughout Sept 29-Oct 01, 2016 Miami, USA, with the theme “Review of Advancements and therefore the Impacts of the Analytical & Bioanalytical Techniques”. and 

World Congress on Biotherapeutics scheduled during May 22-23, 2017 at Mexico, USA with a theme of "Empowering Innovation with Right Tools and Techniques".


Past Reports  Gallery  

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date May 22-23, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2
Poster Opportunity Available

Conferenceseries Destinations